

List of Progress in Hematology "Review Series" 2016-2017

*****2017*****

Epigenetics in hematological malignancies (Edited by Atsushi Iwama)

1. Yang W, Ernst P. SET/MLL family proteins in hematopoiesis and leukemia. *Int J Hematol.* 2017; 105:7-16.
2. Chiba S. Dysregulation of TET2 in hematologic malignancies. *Int J Hematol.* 2017; 105:17-22.
3. Sashida G, Iwama A. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. *Int J Hematol.* 2017; 105:23-30.
4. Mazumdar C, Majeti R. The role of mutations in the cohesin complex in acute myeloid leukemia. *Int J Hematol.* 2017; 105:31-6.

Extracellular Molecules in Hematopoietic Stem Cell Mobilisation (Edited by Susan K. Nilsson)

1. Bendall L. Extracellular molecules in hematopoietic stem cell mobilization. *Int J Hematol.* 2017; 105:118-28.
2. Tay J, Levesque JP, Winkler IG. Cellular players of hematopoietic stem cell mobilization in the bone marrow niche. *Int J Hematol.* 2017; 105:129-40.
3. Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. *Int J Hematol.* 2017; 105:141-52.
4. Texier L, Lineburg KE, MacDonald KPA. Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes. *Int J Hematol.* 2017; 105:153-61.

Leukemia stem cell: its target, environment, and genetics (Edited by Fumihiko Ishikawa)

1. Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. *Int J Hematol.* 2017; 105:549-57.
2. Mu LL, Ke F, Guo X-L, Cai J-J, Hong D-L. Neoplasms in the bone marrow niches: disturbance of the microecosystem. *Int J Hematol.* 2017; 105:558-65.

3. Camacho V, McClearn V, Patel S, Welner RS. Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment. *Int J Hematol.* 2017; 105:566-77.

Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects (Edited by Hironori Harada)

1. Itzykson R, Duchmann M, Lucas N, Solary E. CMML: Clinical and molecular aspects. *Int J Hematol.* 2017; 105:711-19.
2. Yoshimi A, Abdel-Wahab O. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. *Int J Hematol.* 2017; 105:720-31.
3. Makishima H. Somatic SETBP1 mutations in myeloid neoplasms. *Int J Hematol.* 2017; 105:732-42.
4. Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. *Int J Hematol.* 2017; 105:743-7.

Hematopoietic stem cells (Edited by Hideaki Nakajima)

1. Karigane D, Takubo K. Metabolic regulation of hematopoietic and leukemic stem/progenitor cells under homeostatic and stress conditions. *Int J Hematol.* 2017; 106:18-26.
2. Takizawa H, Manz MG. Impact of inflammation on early hematopoiesis and the microenvironment. *Int J Hematol.* 2017; 106:27-33.
3. Kunimoto H, Nakajima H. Epigenetic dysregulation of hematopoietic stem cells and preleukemic state. *Int J Hematol.* 2017; 106:34-44.
4. Asada N, Takeishi S, Frenette PS. Complexity of bone marrow hematopoietic stem cell niche. *Int J Hematol.* 2017; 106:45-54.

Familial predisposition of myeloid malignancies: Biological and clinical significances of recurrent germline mutations (Edited by Hirotaka Matsui)

1. Cheah JJC, Hahn CN, Hiwase DK, Scott HS, Brown AL. Myeloid neoplasms with germline DDX41 mutation. *Int J Hematol.* 2017; 106:163-74.

2. Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM. Heterogeneity of GATA2-related myeloid neoplasms. *Int J Hematol.* 2017; 106:175-82
3. Hayashi Y, Harada Y, Huang G, Harada H. Myeloid neoplasms with germ line RUNX1 mutation. *Int J Hematol.* 2017; 106:183-8.
4. Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. *Int J Hematol.* 2017; 106:189-95.

DNA damage repair network (Edited by Shuki Mizutani)

1. Mizutani S. DNA damage response and disorders with hematology, oncology and immunology. *Int J Hematol.* 2017; 106:326-7.
2. Cheung RS, Taniguchi T. Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers. *Int J Hematol.* 2017; 106:335-44.
3. Takagi M. DNA damage response and hematological malignancy. *Int J Hematol.* 2017; 106:345-56.
4. Morio T. Recent advances in the study of immunodeficiency and DNA damage response. *Int J Hematol.* 2017; 106:357-65.

2016

Management and analyses of registry database of hematopoietic stem cell transplantation in Japan (Edited by Yoshinobu Kanda)

1. Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). *Int J Hematol.* 2016; 103:3-10.
2. Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. *Int J Hematol.* 2016; 103:11-9.
3. Kuwatsuka Y. Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other

countries. *Int J Hematol.* 2016; 103:20-4.

Mesenchymal Stromal/Stem Cells (Edited by Yasuo Miura)

1. Miura Y. Human bone marrow mesenchymal stromal/stem cells: current clinical applications and potential for hematology. *Int J Hematol.* 2016; 103:122-8.
2. Kim N, Cho S-G. Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. *Int J Hematol.* 2016; 103:129-37.
3. Mabuchi Y, Matsuzaki Y, Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs. *Int J Hematol.* 2016; 103:138-44.
4. Nguyen TM, Arthur A, Gronthos S. The role of Eph/ephrin molecules in stromal–hematopoietic interactions. *Int J Hematol.* 2016; 103:145-54.
5. Miyamura K. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns. *Int J Hematol.* 2016; 103:155-64.

Pediatric MDS/MPN (Edited by Atsushi Manabe)

1. Hasegawa D. The current perspective of low-grade myelodysplastic syndrome in children. *Int J Hematol.* 2016; 103:360-4.
2. Sashida S. Evolution of myeloid leukemia in children with Down syndrome. *Int J Hematol.* 2016; 103:365-72.
3. Dalle J-H, de Latour RP. Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. *Int J Hematol.* 2016; 103:373-9.
4. Kook H, Chung N-G, Kang HJ, Im HJ. Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology. *Int J Hematol.* 2016; 103:380-6.

Regulation of hematopoietic stem cells (Edited by Hideo Ema)

1. Hao S, Chen C, Cheng T. Cell cycle regulation of hematopoietic stem or progenitor cells. *Int J Hematol.* 2016; 103:487-97.
2. Wang Z, Ema H. Mechanisms of self-renewal in hematopoietic stem cells. *Int J Hematol.* 2016; 103:498-509.
3. Xiaomin W, Yajing C, Weili W, Weiping Y. mTORC signaling in hematopoiesis. *Int J Hematol.* 2016; 103:510-8.
4. Yu Z, Yingdai G. Novel chemical attempts at ex vivo hematopoietic stem cell expansion. *Int J Hematol.* 2016; 103:519-29.

Epigenetic and metabolic regulation in hematopoiesis/leukemogenesis (Edited by Atsushi Hirao)

1. Jiang Y, Nakada D. Cell intrinsic and extrinsic regulation of leukemia cell metabolism. *Int J Hematol.* 2016; 103:607-16.
2. Celik H, Kramer A, Challen GA. DNA methylation in normal and malignant hematopoiesis. *Int J Hematol.* 2016; 103:617-26.
3. Inoue S, Lemonnier F, Mak TW. Roles of IDH1/2 and TET2 mutations in myeloid disorders. *Int J Hematol.* 2016; 103:627-33.
4. Takamatsu-Ichihara E, Kitabayashi I. The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies. *Int J Hematol.* 2016; 103:634-42.

Current Gene therapy for hematological disorders (Edited by Masato Yamamoto and Kenzaburo Tani)

1. Yamamoto M, Tani K. Current status and recent advances of gene therapy in hematological diseases. *Int J Hematol.* 2016; 104:4-5.
2. Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. *Int J Hematol.* 2016; 104:6-17.
3. Osborn MJ, Belanto JJ, Tolar J, Voytas DF. Gene editing and its application for hematological diseases. *Int J Hematol.* 2016; 104:18-28.
4. Domingo-Musibay E, Yamamoto M. Gene and virotherapy for hematological malignancies. *Int J Hematol.* 2016; 104:29-41.
5. Tani K. Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world. *Int J Hematol.* 2016; 104:42-72.

Recent advance in the diagnosis and treatment of bone marrow failure syndromes (Edited by Shinji Nakao)

1. Nakao S. Diagnostic problems in acquired bone marrow failure syndromes. *Int J Hematol.* 2016; 104:151-2.
2. Narita A, Kojima S. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. *Int J Hematol.* 2016; 104:153-8.
3. Marsh JCW, Mufti GJ. Clinical significance of acquired somatic mutations in aplastic anaemia. *Int J Hematol.* 2016; 104:159-67.
4. Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. *Int J Hematol.* 2016; 104:168-74.

Mechanisms of action of novel drugs in multiple myeloma and those responsible for the acquired resistance (Edited by Shinsuke Iida)

1. Iida S. Mechanisms of action and resistance for multiple myeloma novel drug treatments. *Int J Hematol.* 2016; 104:271-2.
2. Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. *Int J Hematol.* 2016; 104:273-80.
3. Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. *Int J Hematol.* 2016; 104:281-92.
4. Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. *Int J Hematol.* 2016; 104:293-9.
5. Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. *Int J Hematol.* 2016; 104:300-9.